Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Study casts fresh doubt on rosiglitazone

A study has found fresh evidence that the diabetes drug rosiglitazone is associated with an increased risk of congestive heart failure, acute myocardial infarction and mortality.The retrospective study of 159,026 patients aged over 66 during a four year period showed rosiglitazone increased the risk of congestive heart failure by 60%, myocardial infarction by 40% and death by 29% compared with other oral hypoglycaemic agent combination therapies.It ...

Subscribe for full online access and get...

  • Full, instant access to all stories
  • Customised email alerts straight to your inbox
  • 5,000+ practice articles in our clinical archive
  • Online learning units on fundamental aspects of nursing care

Register for guest access to keep reading and get...

  • A free taste of other selected news stories
  • Daily email newsletters

Speak with a member of the team about providing Nursing Times for your whole team
Are you a student nurse? Take advantage of a discounted rate by clicking here (Graduation date required)
Already have an account? Sign in